An Updated Landscape Analysis for the Priority List of Adverse Events of Special Interest (AESI): Chikungunya is now available on Zenodo.
A landscape analysis a comprehensive review of the latest evidence, identifying possible adverse events of special interest (AESI) that may be associated with Chikungunya vaccines, research gaps, and priorities for monitoring vaccine safety. This helps guide public health strategies, regulatory decisions, and future research.
What is Chikungunya?
Chikungunya is a mosquito-borne viral disease that has caused outbreaks in over 110 countries, with millions of cases worldwide. While rarely fatal, it can lead to severe joint pain and arthritis that can last for months or longer, causing disability that can impact a patient’s quality of life and their livelihood, as well as severe manifestations like hepatitis and encephalitis, making vaccine development and safety monitoring essential.
What’s New in This Update?
✅ Refinements to the AESI List – Incorporating the latest evidence and expert recommendations.
Why This Matters
A strong vaccine safety framework is essential for maintaining public trust and guiding evidence-based policy decisions. This updated analysis supports researchers, regulators, and public health professionals in proactively assessing potential safety concerns using a harmonized approach across studies and vaccines.
The AESI list in turn is used to identify needed tools and resources that facilitate using a harmonized approach to safety assessment throughout the vaccine life cycle – from pre-licensure trials to post-marketing pharmacovigilance thus ensuring the continued success of chikungunya vaccination efforts.
Read the full report HERE.
